Top Story

FDA approves first mesenchymal stromal cell therapy

FDA approves first mesenchymal stromal cell therapy

19-Dec-2024

|

By Clara Rodriguez Fernandez

Editor's Choice

FDA approves first-ever gene therapy to be directly administered to the brain

FDA approves first-ever gene therapy to be directly administered to the brain

19-Nov-2024

|

By Clara Rodriguez Fernandez

Headlines

Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2

Teva and Sanofi’s IBD drug hits Phase 2 targets

Orexo and Abera collaborate to develop nasal powder vaccines

nChroma Bio formed by merging genetic medicine companies

SpliceBio gets FDA green light to start Phase 1/2 trial for...

Relation and GSK join forces to advance fibrotic diseases and...

→

In focus

Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases

07-Nov-2024 By Larissa Warneck-Silvestrin

Investing in high-purity guide RNA to unlock the power of CRISPR therapies

Paid for and content provided by Sumitomo Chemical Europe

Abzena announces major expansion of its biologics manufacturing facility

31-Oct-2024 By Larissa Warneck-Silvestrin

Fulfilling Global Temperature-Controlled Transport and Storage Needs for Clinical Trials

Paid for and content provided by Yourway

Featured

Insight

Top 10 rare disease pharma sees 10.4% rise in therapy start

By Liza Laws

Top 10 rare disease pharma sees 10.4% rise in therapy start

Bio developments

→

Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2

Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2

19-Dec-2024

By Helen Albert

Teva and Sanofi’s IBD drug hits Phase 2 targets

Teva and Sanofi’s IBD drug hits Phase 2 targets

17-Dec-2024

By Helen Albert

Orexo and Abera collaborate to develop nasal powder vaccines

Orexo and Abera collaborate to develop nasal powder vaccines

17-Dec-2024

By Larissa Warneck-Silvestrin

Partner insightMore →

Internal Standard (IS) Variation Case Studies: Emerging from Three Common IS Challenges

Content provided by WuXi AppTec

ICH M10 Guidance: Harmonization and Modification to Bioanalytical Method Variation

Content provided by WuXi AppTec

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences

Markets & regulation

→

FDA approves first mesenchymal stromal cell therapy

FDA approves first mesenchymal stromal cell therapy

19-Dec-2024

By Clara Rodriguez Fernandez

Cell and gene therapy access model launches in US

Cell and gene therapy access model launches in US

05-Dec-2024

By Helen Albert

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

26-Nov-2024

By Helen Albert

Helen Harrington’s journey: Patience, passion, and problem-solving

Helen Harrington’s journey: Patience, passion, and problem-solving

20-Nov-2024

By Liza Laws

Contract manufacturing & logistics

→

Eli Lilly invests $3bn in injectable drug manufacturing facility

Eli Lilly invests $3bn in injectable drug manufacturing facility

10-Dec-2024

By Clara Rodriguez Fernandez

Adragos Pharma snaps up Baccinex to expand CDMO network

Adragos Pharma snaps up Baccinex to expand CDMO network

26-Nov-2024

Abzena’s advanced drug development showcased at CPHI Milan

Abzena’s advanced drug development showcased at CPHI Milan

01-Nov-2024

By Liza Laws

CRO NovAliX teams with Bruker to advance drug development

CRO NovAliX teams with Bruker to advance drug development

29-Oct-2024

By Liza Laws

Expand your knowledge

Industry Newsletters

Choose from regular, topic-based and special edition briefings

Resource centre

Discover cutting edge insight from our partners

Events & webinars

Explore our programme of live & on-demand content